Renal Cancer - Results from #380

Dose-effect Relationship of Kidney Function After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: Trog 15.03 Fastrack Ii. April 30, 2024

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). April 30, 2024

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. April 29, 2024

Network analysis of histopathological image features and genomics data improving prognosis performance in clear cell renal cell carcinoma. April 29, 2024

A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma. April 26, 2024

First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy. April 26, 2024

Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma. April 25, 2024

Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles. April 25, 2024

Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Renal Cell Carcinoma in England: A Retrospective Cohort Study. April 24, 2024

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. April 24, 2024

Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer. April 23, 2024

Avoiding "Needless" nephrectomy: What is the role of small renal mass biopsy in 2024? April 23, 2024

Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis. April 23, 2024

Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure-Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibito April 22, 2024

Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. April 22, 2024

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. April 19, 2024

Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. April 19, 2024

Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27. April 19, 2024

Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma. April 18, 2024

VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis. April 18, 2024

Page 20 of 456